Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 13.8% – Still a Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price traded up 13.8% on Monday . The company traded as high as $98.00 and last traded at $102.9250. 138,930 shares were traded during trading, a decline of 79% from the average daily volume of 664,267 shares. The stock had previously closed at $90.43.

Wall Street Analyst Weigh In

KYMR has been the topic of several research reports. Loop Capital set a $97.00 price target on Kymera Therapeutics in a report on Monday, June 8th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. UBS Group boosted their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Jefferies Financial Group assumed coverage on Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $117.14.

Kymera Therapeutics Stock Performance

The firm’s 50 day simple moving average is $83.16 and its 200-day simple moving average is $81.06. The company has a market capitalization of $8.13 billion, a price-to-earnings ratio of -27.74 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Elena Ridloff sold 7,400 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $85.37, for a total value of $631,738.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bruce Booth sold 5,900 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 143,107 shares of company stock worth $12,008,834 over the last ninety days. 15.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $63,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $73,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.